Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study and are willing to sign a consent form before any study procedures begin.
- People who have been diagnosed with lymphoma.
- People who will be receiving one of two specific chemotherapy treatment plans for lymphoma (called R-CHOP or POLA-R-CHP) as their first treatment — there is no requirement to be a certain amount of time from diagnosis.
- People who are 18 years of age or older.
- People who currently do 60 minutes or less of structured moderate or vigorous exercise per week.
- People whose doctor has given approval for them to participate in exercise.
- People who speak English.
- People who are willing to travel to Dana-Farber Cancer Institute for data collection and exercise sessions.
- People who have access to a phone that can receive text messages.
Who may not be able to join:
- People who have unstable health conditions that would make it unsafe to participate in moderate to vigorous exercise.
- People who have been doing more than 60 minutes of structured moderate to vigorous exercise per week over the past month.
- People who are currently being treated for another active cancer (except a common type of skin cancer called basal cell carcinoma).
- People who are currently taking medication for weight loss.
- People who, in the opinion of the study investigators, may not be able to safely follow the study's monitoring requirements.
- People who are unable to travel to the Dana-Farber Cancer Institute Longwood campus for data collection and chemotherapy treatment sessions.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christina Dieli-Conwright, MD, PhD, Dana-Farber Cancer Institute
Phone: 617-582-8321
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Intervention Completion Rate (Feasibility); Refusal Rate; Retention Rate; Acceptability of Intervention Measure (AIM) Scale; Acceptability Exit Survey
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.